Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,132.95 +54.09 (+0.67%) Bitcoin USD
64,706.18 +974.35 (+1.53%) CMC Crypto 200
1,338.36 -58.17 (-4.16%)
Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK)
| Previous close | 1.600 |
| Open | 1.610 |
| Bid | 1.650 x N/A |
| Ask | 1.690 x N/A |
| Day's range | 1.580 - 1.700 |
| 52-week range | 1.380 - 7.770 |
| Volume | |
| Avg. volume | 2,160,263 |
| Market cap | 1.338B |
| Beta (5Y monthly) | 0.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.500 |
| Earnings date | 28 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.41 |
PR NewswireJacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting
Jacobin Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that the company will present the results of two preclinical evaluation of PARP7 inhibitor JAB-26766 and p53 Y220C reactivator JAB-30355 in form of the abstract during the American Association for Cancer Research (AACR) Annual Meeting 2024 (the "AACR 2024") from April 5 to 10, 2024.
PR NewswireJacobio Pharma Announces 2023 Annual Results
Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its 2023 annual results. The revenue was RMB63.5 million, the R&D investment was RMB372 million, the cash and cash equivalent at the end of 2023 was RMB 1.2 billion. Jacobio Pharma also announced its recent business progress and expected milestones.
PR NewswireJacobio Pharma Receives IND Approval for P53 Y220C Activator JAB-30300 in the U.S.
Jacobio Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced it received IND (Investigational New Drug) approval of its self-developed drug JAB-30300 (P53 Y220C activator) from the FDA of the U.S. Jacobio plans to initiate a Phase I/IIa advanced solid tumors clinical trial in the U.S., to evaluate safety and efficacy of JAB-30300. Jacobio also plans to submit IND in China, and will conduct clinical studies once receives the IND approval.
